Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections Interventions: Biological: GEO-D02 DNA; Biological: MVA/HIV62B Vaccine; Biological: B63521^11 gp120; Biological: IHV01 Protein; Biological: Protein Placebo Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network (HVTN), Fred Hutch / University of Washington; GeoVax Labs, Inc; Duke University; Institute of Human Virology, School of Medicine, University of Maryland Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Infectious Diseases | Research | University of Maryland | University of Washington | Vaccines | Virology